Pfizer Inc (PFE) Quote - XNYS | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Premium

Is it the right time to buy or sell?

Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Pfizer Posts Solid 4Q as COVID-19 Vaccine Is Well Positioned for Huge Near-Term Growth in 2021

Sector Director Damien Conover

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA | Feb 2, 2021

Pfizer reported fourth-quarter results largely in line with our expectations, and we don’t expect any major changes to our fair value estimate. We continue to view the stock as undervalued with the market not appreciating the long-term potential growth coming from recently launched drugs and an improving pipeline, which also reinforces our wide moat rating.

Read Full Analysis

Company Profile

Business Description

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

Contact

235 East 42nd Street
New York, NY, 10017

T +1 212 733-2323

Sector Healthcare

Industry Drug Manufacturers - General

Most Recent Earnings Dec 31, 2020

Fiscal Year End Dec 31, 2021

Stock Type High Yield

Employees 78,500

Related

These Sectors Performed Best and Worst in the Pandemic

We look at the industries for those most affected by social-distancing and stay-at-home orders.

Sachin Nagarajan

3 Warren Buffett Stocks to Buy

These undervalued stocks are among the top holdings in Berkshire Hathaway today.

Susan Dziubinski

5 Undervalued Dividend-Growth Stocks

These heavily weighted names in the Morningstar US Dividend Growth Index are all at least 10% undervalued.

Susan Dziubinski

Stock Analyst Update

Pfizer Vaccine Shows Promise for Huge Near-Term Growth

The wide-moat company posted a solid fourth quarter. We continue to view the stock as undervalued.

Stock Analyst Update

J&J Releases COVID-19 Vaccine Data

The data doesn't significantly alter our valuation or U.S. herd immunity forecast.

The Week Ahead: Google, Amazon, and Pfizer to Report Earnings

Other big names in the energy and healthcare sectors are on the calendar for the week ahead as well.

Carole Hodorowicz

Stock Strategist Industry Reports

COVID-19 Sales Have No Major Impact on Drug and Vaccine Manufacturers We Cover

However, the biopharma industry's ability to adapt and innovate to treat disease reinforces our moat ratings.

Stock Strategist Industry Reports

COVID-19 Vaccine Distribution and Herd Immunity to End Pandemic

Successful vaccine development and rollout will boost industry goodwill and reduce ESG risk, but we’re keeping our valuations steady.

Healthcare Outlook: Coronavirus at Center Stage

And some undervalued stocks that capture our attention.

Quarter-End Insights

Outside of Aerospace and Defense, Few Undervalued Industrials Stocks

Incoming administration could be a boon for infrastructure spending.

The Value Rebound Is Good News for Dividend Investors

Equity income is well-positioned, both short- and long-term.

Digging Into Berkshire Hathaway’s Portfolio

Morningstar’s Global Risk Model reveals how the investment giant’s equity holdings stack up on 11 measures of risk.

Stock Analyst Update

FDA Supports EUA for Pfizer-BioNTech’s COVID-19 Vaccine

The FDA provided emergency use authorization, or EUA, for Pfizer and partner BioNTech’s COVID-19 vaccine BNT162b2 on Dec. 11. However, we are not changing our fair value for either Pfizer or BioNTech as the EUA was largely expected.

Stock Strategist Industry Reports

Implementation of Trump's Drug-Pricing Orders Unlikely

We don't foresee any impact on pharma companies' moats or valuations.

3 Undervalued Stocks in Berkshire's Portfolio

We think these holdings are bargains.

Susan Dziubinski

Stock Analyst Update

Pfizer/BioNTech Report 95% Efficacy Rate for Vaccine

After reporting strong final data, we expect emergency authorization of Pfizer and BioNTech's vaccine by early December.

We’ve Seen a Post-Election Small-Value Rally Before

But this one could really end differently.

Stock Strategist Industry Reports

Are Generics Back in Vogue?

Stabilizing pricing and improved efficiencies should lead to steady gains and needed debt repayments for the generic drugmakers.

Finally Time for Value Stocks to Shine?

As the pathway to economic normalization in 2021 becomes clear, the market has begun to favor value stocks over growth stocks.

A Dramatic Reversal in the Market

Those value funds you own that have annoyed you? Take a look now. Many are surging.